Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
  di: Toshifumi Tada, et al.
  Pubblicazione: (2025)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease
  di: Yi‐Ting Chen, et al.
  Pubblicazione: (2024)
• Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Akihito Shiomi, et al.
  Pubblicazione: (2024)
• Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
  di: Donghee Kim, et al.
  Pubblicazione: (2024)